{"denoms":[{"counts":[{"groupId":"BG000","value":"147"}],"units":"Participants"}],"groups":[{"description":"Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0\n\nTherapeutic allogeneic lymphocytes: A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.\n\nBusulfan: Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.\n\nIV Busulfan is available and diluted and administered per package insert guidelines.\n\nCyclosporine: Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including","id":"BG000","title":"Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"81"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"66"}],"title":">=65 years"}],"denoms":[{"counts":[{"groupId":"BG000","value":"147"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"49"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"98"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"147"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"91"}],"title":"KPS ≥ 90"},{"measurements":[{"groupId":"BG000","value":"48"}],"title":"KPS < 90"}],"denoms":[{"counts":[{"groupId":"BG000","value":"139"}],"units":"Participants"}]}],"description":"KPS Scale:\n\n100 = Normal, no complaints, no evidence of disease. 90 = Able to carry on normal activity; minor signs or symptoms of disease. 80 = Normal activity with effort; some signs or symptoms of disease. 70 = Cares for self, unable to carry on normal activity or to do active work. 60 = Requires occasional assistance, but is able to care for most of his/her needs.\n\n50 = Requires considerable assistance and frequent medical care. 40-0 = Not eligible","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eight patients did not have KPS status available, which is why the values do not add up to the total number of participants.","title":"Karnofsky Performance Score (KPS)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"85"}],"title":"In Complete Remission"},{"measurements":[{"groupId":"BG000","value":"62"}],"title":"Not in Complete Remission"}],"denoms":[{"counts":[{"groupId":"BG000","value":"147"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Pre-Transplant Disease Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"93"}],"title":"Low or intermediate"},{"measurements":[{"groupId":"BG000","value":"51"}],"title":"High or Very High"}],"denoms":[{"counts":[{"groupId":"BG000","value":"144"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"DRI was unclassifiable in 3 patients.","title":"Disease Risk Index (DRI)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"135"}],"title":"8/8"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"7/8"}],"denoms":[{"counts":[{"groupId":"BG000","value":"147"}],"units":"Participants"}]}],"description":"HLA Criteria:\n\nRelated to the patient and genotypically or phenotypically HLA-identical (8/8). Single antigen mismatch (7/8) can be accepted if no other donor is available.\n\nOR\n\nUnrelated to the patient and HLA matched by molecular typing, allowing a single allele or antigen mismatch (7/8).","paramType":"COUNT_OF_PARTICIPANTS","title":"HLA Match","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"}],"title":"Related Sibling Donor"},{"measurements":[{"groupId":"BG000","value":"108"}],"title":"Unrelated Donor"}],"denoms":[{"counts":[{"groupId":"BG000","value":"147"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Donor Relation","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}],"title":"-/- recipient/donor"},{"measurements":[{"groupId":"BG000","value":"118"}],"title":"All other combinations"}],"denoms":[{"counts":[{"groupId":"BG000","value":"140"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Cytomegalovirus (CMV) status was unavailable in 7 patients.","title":"Cytomegalovirus (CMV) Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"117"}],"title":"F/F, M/M, M/F"},{"measurements":[{"groupId":"BG000","value":"30"}],"title":"F/M"}],"denoms":[{"counts":[{"groupId":"BG000","value":"147"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Donor/Recipient Gender","unitOfMeasure":"Participants"}]}